Page 31 - 22-0424

The International Journal of the Royal Society of Thailand
Volume XI - 2019

Pukrittayakamee S, Chantra A, Simpson J, Vanijanonta S, Clemens R, Looareesuwan
S, et al. Therapeutic responses to different antimalarial drugs in vivax
malaria. Antimicrob Agents Chemother. 2000;44(6):1680–85. doi:10.1128/

aac.44.6.1680-1685.2000.
Pukrittayakamee S, Chotivanich K, Chantra A, Clemens R, Looareesuwan S,

White NJ. Activities of artesunate and primaquine against asexual- and
sexual-stage parasites in falciparum malaria. Antimicrob Agents Chemother.
2004;48(4):1329–1334. doi:10.1128/aac.48.4.1329-1334.2004.
Pukrittayakamee S, Imwong M, Stepniewska K, White N, Singhasivanon P, Day
N. Effects of different antimalarial drugs on gametocyte carriage in P. Vivax
malaria. Am J Trop Med Hyg. 2008;79(3):378–384. doi:10.4269/
ajtmh.2008.79.378.

Pukrittayakamee S, Imwong M, Chotivanich K, Singhasivanon P, Day NP, White
NJ. A comparison of two short-course primaquine regimens for the

treatment and radical cure of Plasmodium vivax malaria in Thailand. Am J
Trop Med Hyg. 2010;82:542–547.
Pukrittayakamee S, Tarning J, Jittamala P, Charunwatthana P, Lawpoolsri S,
Lee SJ, et al. Pharmacokinetic interactions between primaquine and
chloroquine. Antimicrob Agents Chemother. 2014;58:3354–3359.
doi:10.1128/AAC.02794-13.

van der Pluijm R, Tripura R, Hoglund R, Pyae Phyo A, Lek D, ul Islam A, et al.
Triple artemisinin-based combination therapies versus artemisinin-based
combination therapies for uncomplicated Plasmodium falciparum malaria: a
multicentre, open-label, randomised clinical trial. Lancet. 2020;395

(10233):1345–1360. doi:10.1016/S0140-6736(20)30552-3.
von Seidlein L, Hanboonkunupakarn B, Jittamala P, Pukrittayakamee S. RTS,
S/AS01, a vaccine targeting pre-erythrocytic stages of Plasmodium
falciparum. Emerg Top Life Sci. 2017;1:533–537. doi:10.1042/ETLS20170101.

von Seidlein L, Hanboonkunupakarn B, Jittamala P, Pongsuwan P, Chotivanich
K, Tarning J, et al. Combining antimalarial drugs and vaccine for malaria
elimination campaigns: a randomised safety and immunogenicity trial of
RTS,S/AS01 administered with dihydroartemisinin, piperaquine and

25
Sasithon Pukrittayakamee et al.

11/7/2565 BE 13:27
_22-0424(011-026)3.indd 25
_22-0424(011-026)3.indd 25 11/7/2565 BE 13:27